Neurohistopathological Findings of the Brain Parenchyma After Long-Term Deep Brain Stimulation: Case Series and Systematic Literature Review

AUTHORS

Juan Vivanco-Suarez[1][*], MD; Timothy Woodiwiss[1][*], MD; Kimberly L. Fiock[2], PhD; Marco M. Hefti[2], MD; Nandakumar S. Narayanan[3], MD, PhD; Jeremy D. W. Greenlee[1], MD

[*] Both authors contributed equally.

AFFILIATIONS

[1] Department of Neurosurgery, University of Iowa, Iowa City, IA, United States

[2] Department of Pathology, University of Iowa, Iowa City, IA, United States.

[3] Department of Neurology, University of Iowa, Iowa City, IA, United States.

CORRESPONDENCE

Jeremy D. W. Greenlee, MD,

Department of Neurosurgery, University of Iowa Hospitals and Clinics,

200 Hawkins Dr, 1826 JPP, Iowa City, IA 52242, United States.

E-mail address: jeremy-greenlee@uiowa.edu, phone: (319) 356-2771

SHORT RUNNING TITLE

Neurohistopathological findings after deep brain stimulation

KEYWORDS

Parkinson's disease; Neuropathology; Gliosis; Postmortem

ELEMENTS COUNTS

Abstract: 299 words

Text: 3372 words

References: 48

Tables: 2

Figures: 1

Supplemental tables: 5

Supplemental figures: 0

PREVIOUS PRESENTATION

None

ETHICS

None

CONFLICTS OF INTEREST

The authors report no disclosures.

FUNDING

This research received no specific grant from any funding agency in public, commercial, or not-for-profit sectors.

Neurohistopathological Findings of the Brain Parenchyma After Long-Term Deep Brain Stimulation: Case Series and Systematic Literature Review

ABSTRACT

Introduction: The efficacy of deep brain stimulation (DBS) has been established to treat several movement and psychiatric disorders. However, several aspects, such as the mechanism of action and tissue changes after treatment are incompletely described. Hence, we aimed to describe the neurohistopathological findings of 9 patients who underwent DBS for movement disorders. Additionally, we performed a systematic literature review on postmortem studies after DBS implantation.

Methods: We performed a retrospective study of patients who underwent DBS for movement disorders between 2000-2023 and had postmortem autopsy. Demographic, clinical, and outcomes were collected. Levodopa equivalent daily dose (LEDD) and total electrical energy delivered (TEED) were calculated. Neurohistopathological assessments were performed from autopsies. A systematic literature review was conducted to summarize the literature.

Results: Postmortem neurohistopathologic assessment of 9 patients who underwent DBS for movement disorders (8 Parkinson's disease [multiple system atrophy was final diagnosis in 1], and 1 parkinsonism) was performed. Median age at DBS implantation was 65 years (range, 54-69), and most were male (8 patients, 89%). Most common DBS target was the subthalamic nucleus (8 patients, 89%). Median DBS duration was 65 months (range, 7-264 months). Reduction in LEDD was found in 6/8 patients and TEED was increased 4/6 patients. No patients died due to DBS. Neurohistopathological assessment showed gliosis in 7 (77.7%) patients and activated microglial infiltration in 1 (11%). Additionally, postmortem findings (after DBS) of 59 patients (between 1977-2021) were identified in the literature: 26 (44.1%) for Parkinson's disease, 20 (33.9%) for pain, and 13 (22%) for other conditions.

Conclusion: Our findings confirm the presence of a local tissue reaction, including gliosis and activated microglial infiltration around the implanted DBS electrodes. The effect of the local changes on the clinical efficacy of DBS is not established. Further DBS postmortem studies and standardization of tissue processing are needed.

ABBREVIATIONS

DBS, deep brain stimulation; LEDD, Levodopa equivalent daily dose; MSA, multiple system atrophy; PD, Parkinson's disease; TEED, total electrical energy delivered.

INTRODUCTION

The efficacy of deep brain stimulation (DBS) has been established for the treatment of several movement and psychiatric disorders.[1] Furthermore, its experimental application for chronic pain, obesity, and other neurocognitive disorders has continually expanded, aiming to benefit a broader group of patients.[2] However, several aspects of this treatment are not completely defined, including the specific interaction and activation of surrounding structures, the local tissue changes in the brain caused by long-term stimulation, the potential adverse tissue responses induced by the electrode, and the existence of neuronal damage.[1,3] A deeper understanding of the chronic local glial responses after electrode implantation may provide helpful insights for the improvement of anatomical targets and the optimization of electrode design according to the target tissue.

Previously published postmortem studies have begun the characterization of histological changes occurring around electrodes in response to implantation and chronic stimulation. A comprehensive review performed by DiLorenzo et al. reported 40 cases with implanted systems from as early as 1977.[4] The authors showed that in more than 50% of the cases, there was local fibrosis, astrocytosis, multinucleated giant cells, mononuclear leukocytes, macrophages, activated microglia, and neuronal loss.[4,5] Of note, persistent efficacy was more commonly observed when tissue injury was absent. More recently, Vedam-Mai et al. found that 3 out of 4 DBS cases exhibited histopathological evidence of a glial collar or scar around the electrode, but there was no significant association between DBS duration and the amount of gliosis. As the technologies and techniques employed for DBS continue to evolve, the evidence regarding the local changes around the electrode is contradictory.[6-9] For instance, data on the comparison of histological samples from patients with active and inactive electrodes is limited, the effect of the size of the gliotic scar is uncertain, and evidence of the distance (from the electrode) where neuronal loss or preservation is observed is unclear.[10]

Hence, this study aims to characterize and describe the neurohistopathological environment of the brain parenchyma surrounding DBS electrodes in 9 patients who underwent surgical treatment for Parkinson's disease (PD) or a parkinsonism syndrome. Additionally, we present an updated and expanded summary of the literature on this topic with a systematic review of postmortem studies after DBS implantation.

METHODS

Study design, patient protocol, tissue acquisition, and storage

This was a retrospective study of adult patients who underwent DBS for movement disorders at a tertiary academic center between July 2000 and April 2023. All tissue was obtained from autopsies conducted at the University of Iowa Hospitals and Clinics as part of routine clinical care in accordance

with all applicable federal and state laws and regulations. Consent for the use of tissue in research was

obtained from the next of kin as part of the autopsy consent. This project was reviewed by the University

of Iowa Institutional Review Board and determined not to represent human subjects research under the

National Institutes of Health Revised Common Rule. Based on the database created for each donor, for

this study, we extracted the age at diagnosis, sex, duration of disease, calculated Levodopa equivalent

daily dose (LEDD)[11] (before implantation, 6 [± 3] months after DBS, and at last clinical follow-up), age

at DBS implantation, intraoperative and hospitalization complications, DBS duration, post-implantation

stimulation parameters (at 6 [± 3] months after DBS, at last clinical follow-up), and age at death. To

assess the stimulation parameters, we calculated total electrical energy delivered (TEED)[12] (impedance

was set to 1000Ω to standardize calculations).

Neurohistopathological techniques and evaluation

123 Tissue processing was done as previously described.[13-15] Briefly, brains were fixed in 20% neutral

124 buffered formalin for 10-14 days and then sectioned, sampled, processed, and stained (both histochemical

125 and immunohistochemical stains) in the Emory Warner Clinical Pathology Laboratories of the University

126 of Iowa according to standard protocols. A board-certified neuropathologist (MMH) and PhD-trained

127 research neuropathologist (KLF) reviewed all tissue sections and stains.

Systematic literature review and data extraction

A comprehensive literature search of the MEDLINE (via PubMed) database using medical subject

heading terms, entrees, and free text to identify all published postmortem neurohistopathological reports

of DBS cases (end-of-search date: August 9, 2023). The complete search strategy is found in

Supplemental Table 1. All DBS cases, regardless of indication or anatomical target in the human brain,

were included. Review articles or meta-analyses that did not describe disaggregated data on DBS cases

were excluded. Two independent reviewers (TW and JV-S) screened the articles using the Rayyan tool

(https://www.rayyan.ai/). Any difference between reviewers was settled through discussion. After the

initial selection of eligible studies, the reference lists were thoroughly searched to identify additional

eligible studies based on the "snowball" methodology.[16] Because DiLorenzo et al. thoroughly reviewed

the literature in 2014, we expanded our review to new cases either missed by the aforementioned authors

or reported after the review was completed. The following data were collected using a standardized data

extraction form: demographic and patient characteristics, information about implanted hardware,

stimulation parameters, clinical course, and neuropathological findings. Clinical efficacy and decline after

DBS were extracted as defined by the authors of each study. When critical or disaggregated information

was missing, the studies were excluded.

RESULTS

Patient demographics, clinical, and DBS characteristics

A total of 9 patients who had DBS implantation were identified from our institutional autopsy database. The patient and neurohistopathologic characteristics are described in **Table 1**. The median age of disease onset was 52 (range, 47-64 years), and 8 (89%) were male. On preoperative clinical evaluation, PD was diagnosed in 8 (89%) patients and parkinsonism in 1 (11%). Of note, patient 9 presented clinically as PD with a very robust response to levodopa for several years. However, dysautonomic symptoms and ataxia emerged throughout the disease course, pointing to the diagnosis of a slowly evolving Parkinsonian variant multiple system atrophy (MSA), which was confirmed on postmortem neurohistopathologic evaluation.

Regarding the DBS characteristics, the median disease course before DBS implantation was 7 years (range, 3-20 years). The median patient age at DBS implantation was 65 years (range, 54-69 years). All patients received bilateral DBS lead implantation; the majority received electrodes targeting the bilateral subthalamic nuclei (8, 89%). One (11%) patient received electrodes targeting the globus pallidus interna. Patient 3 had an additional electrode implanted at the left ventralis intermedius thalamic nucleus due to refractory right-sided tremor. All electrodes were made of platinum/iridium (Medtronic, Inc.). The median DBS duration was 65 months (range, 7-262 months). Patient 5 underwent DBS removal due to infection surrounding the left-sided extracranial wire, and reimplantation was successful 3 months later after adequate infection management. Patient 8 had a protracted wound healing associated with a chronic infection that failed antibiotic management (DBS was removed 13 months after implantation). At last follow-up, the TEED increased in 4 patients by a mean of 178 J·s. However, in patients 8 and 9, the TEED decreased (1 and 21 J·s, respectively). A mean LEDD reduction of 28% was observed in 6 patients. On the other hand, LEDD increased in patients 4 and 6 by 67% and >100%, respectively. Additional details about the LEDD and TEED are presented in **Supplemental Table 2**. In terms of mortality, 1 patient (11%, case 9) passed away due to disease progression, 4 (44%) died due to unknown causes, and the remaining 4 (44%) passed away due to reasons unrelated to the primary disease or an unknown cause.

Postmortem neurohistopathological characteristics

An example of the gross and microscopic findings is presented in **Figure 1 (A-E)**. **Table 1** shows a descriptive summary of the postmortem neurohistopathologic findings. Findings at the site of DBS were the following: gliosis was encountered in 7 (77.8%) patients and activated microglial infiltration in 1 (11%). From the patients who developed gliosis around the DBS electrode, the median DBS duration was 65 months (range, 13-262). TEED increased in 4 patients (mean of 178 J·s) and decreased in 2 (2% and

31%, respectively). A mean LEDD reduction of 32% was observed in 5 patients. Two patients required an

increase of their LEDD of 67% and >100%, respectively. Notable neurohistopathologic changes from the

tissue sections are the following: substantia nigra depigmentation was found in 2 (22%) patients (cases: 1

and 3) and nigra cell loss in 7 (78%; cases: 1, 4, 5, 6, 7, 8, and 9). Patient 1 had a combination of nigra

depigmentation and nigra cell loss. There were a variety of additional neurodegenerative pathologic

findings, including the presence of Lewy bodies in 5 patients (56%; cases: 2, 3, 4, 5, and 6) at different

anatomical structures, neurofibrillary tangles in 4 (44%; cases: 5, 6, 8, and 9), tau aggregates in 4 (44%;

cases: 2, 5, 8, and 9), beta-amyloid plaques in 3 (33%; cases: 5, 6, and 8), TDP-43 inclusions in 2 (22%;

cases: 2 and 5), and inclusions of alpha-synuclein in 1 (11%, case 9). Finally, other pathological findings

(distant to the tract) including hemorrhages and subacute infarcts were reported in 3 (33%) patients (cases

6, 7, and 8).

Systematic review update: study selection and characteristics

The literature review yielded 1249 articles, from which 18 duplicates were removed. As a result of

the initial screening by title and abstract, there were 48 potentially eligible articles. In the full-text

evaluation, 16 documents were excluded for the following reasons: ineligible study type (*n*=6),

insufficient data available (*n*=5), ineligible outcomes (*n*=3), and ineligible patient population (*n*=2).

Ultimately, 32 studies (25 case reports and 7 case series) from the final systematic search were included.

From the studies, a total of 59 patients who had a postmortem neurohistopathological assessment

after DBS implantation (for different conditions) were identified. The studies were performed between

1977 and 2021. Fifteen were conducted in Europe [6,7,10,17-28], 13 in North America[29-41], 3 in Australia[42-44],

and 1 in Asia[45]. The number of patients per study ranged from 1 to 8. In terms of the conditions for which

DBS was implanted, 26 (44.1%) patients were treated for PD between 1994 and 2021 (**Table 2**; 2 MSA

cases were initially misdiagnosed as PD), 6 (10.2%) for epilepsy (4 cases had cerebellar stimulation)

between 1979 and 2020 (**Supplemental material Table 3**), 20 (33.9%) for pain between 1977 and 1991

(**Supplemental material Table 4**), and 7 (12.1%) for other conditions (tremor, chorea-acanthocytosis,

and diffuse Lewy body disease) between 2000 and 2011 (**Supplemental material Table 5**).

Literature PD patients: DBS characteristics

Regarding the 26 PD patients (cases 11[18] and 15[30] were confirmed to be MSA on autopsy), the age at

DBS implantation ranged from 24 to 81 years, and most were males (21; 80.8%). The DBS targets were

the subthalamic nucleus in 16 (61.5%) patients (15 bilateral and 1 left side), the ventralis intermedius

thalamic nucleus in 8 (30.8%; 3 bilateral, 3 right, 2 left, and 1 unknown), the left centromedian-

parafasicular complex thalamic region in 1 (3.8%), and the bilateral zona incerta in 1 (3.8%).

Platinum/iridium electrodes were the most employed. DBS duration ranged from 2 days to 144 months.

Three cases passed away within 1 month after DBS implantation. Case 9 passed away 2 days after

implantation due to myocardial infarction.[10] Case 11 was readmitted 19 days after electrode placement

surgery due to abnormal behavior, impaired gait, fever, and lethargy. DBS was discontinued, and medical

management was started.[18] However, after transient improvement, the patient died 2 days later due to a

massive pulmonary embolism (identified in autopsy). Case 13 died 4 days after implantation due to

cardiorespiratory arrest secondary to pulmonary embolus (identified in autopsy). Clinical efficacy (as

reported by the authors of each study) was observed in 24 patients (92.3%), and decline was reported in 4

(15.4%). Death causes were diverse. However, none of them were encountered intraoperatively during

DBS implantation.

Literature PD patients: postmortem neurohistopathological characteristics

In terms of the postmortem neurohistopathological analysis, fibrillary gliosis (which represents a

chronic tissue reaction) was reported in 23/24 (92.3%) patients, and in 2/26 (7.7%) patients, it could not

be assessed due to precipitated death (details discussed above). In the patients who passed away within 1

month after implantation, fresh hemorrhage was evidenced in 2/3 (66.7%). Reactive astrocytosis (mostly

reflective of an acute tissue reaction) was observed in 14/25 (56%) patients. Microglial activation was

found in 9/17 (52.9%) patients, and neuronal loss was observed in 7/19 (36.8%) patients. Multinucleated

giant cells were reported in 8/25 (32%) patients. Regarding the pathologic findings of PD, nigra

depigmentation was reported in 24/24 (100%) patients, and nigra cell loss in 21 (80.7%). Of note, in the

cases where MSA was confirmed on autopsy (2/26, 7.7%), DBS showed clinical efficacy only in case 11.

DISCUSSION

In this study of the neurohistopathological findings of 9 patients implanted with platinum/iridium

DBS electrodes for parkinsonism (1 patient), PD (7 patients), and parkinsonian type MSA (1 patient), we

found that at a median time of 65 months after DBS implantation, the brain tissue surrounding the DBS

resulted in gliosis in 7 patients (78%) and the presence of activated microglia in 1 patient (11%). In

general, these results are consistent with previous postmortem studies showing that a glial response is

consistently generated around the DBS electrodes. Additionally, our systematic review spanning between

1977 and 2021 of postmortem neuropathological studies reporting findings after DBS identified 59

unique patients who underwent treatment for PD, epilepsy, pain, and other conditions such as tremor,

chorea-acanthocytosis, and diffuse Lewy body disease. As the number of patients treated with DBS (for a

wide variety of conditions) increases and the technologies continue to evolve, our study represents an

addition to the body of evidence on the postmortem findings after DBS and represents the most

comprehensive and current review of this topic.

Gliosis surrounding the implantation site

The presence of a gliotic response surrounding the DBS electrode described in this study is similar to

the findings reported in previous postmortem human studies and animal models.[2] Yet, our rate of 78%

(7/9 patients) gliotic response after a range of 7-262 months following DBS implantation is lower than the

overall rate of gliotic responses reported in the literature (92%, 22/24 patients). Previous studies have

attributed the reaction of the brain parenchyma to the electrode itself and/or the chronic stimulation.[32]

More study is needed to understand if these factors, such as the biocompatibility of the implanted

electrodes, the variability in the stimulation parameters, degradation of the metal contacts, and the length

of stimulation (and others), could be implicated in the process of gliotic scar formation. The clinical

implication (effect upon efficacy variation) of the gliotic response around the DBS electrode is poorly

described. The plausibility that an increased gliotic response negatively affects DBS efficacy seems

reasonable and intuitive. However, in our study, from the 7 patients who developed gliotic changes, 5 had

a 32% reduction in their LEDD at the last follow up. This contrasted with the 2 patients who needed a

greater than 50% LEDD increase over their post-implantation course. Of note, these patients (4 and 6

from Table 1) had the lowest pre-DBS LEDDs and a prolonged DBS treatment (65 and 94 months,

respectively). Also, patient 6 was the only who received stimulation of the globus pallidus interna. Given

the variability in our findings, the limited sample size, and the lack of standardization in the assessment of

gliosis around the DBS electrode, additional studies will be needed with objective clinical findings, such

as LEDD and TEED, compared to in depth histological evaluation, such as volume and density of gliosis,

before robust conclusions can be made. Separating the gliosis produced by the implantation lesion and the

simulation-induced effects is also relevant for optimizing clinical efficacy. Thus, we recommend that

future studies evaluate the potential correlation between the gliotic scar and the clinical efficacy of DBS

treatment to provide needed insights for developing biocompatible materials, optimizing stimulation

parameters, and implantation techniques that optimize patient outcomes.

Additional neurohistopathologic findings

Evidence of additional markers of local tissue response (to the implanted electrodes), such as

activated microglia, reactive astrocytosis, giant multinuclear cells, hemosiderin-laden macrophages, and

neuronal loss, have been reported in previous studies.[2,4,8] In our series, only one (11%) case (patient 2)

demonstrated activated microglia infiltration, which was lower than the 53% we found in the literature

review. The presence of activated microglia lacks specificity but supports the presence of an ongoing

inflammatory response regardless of the chronicity of the electrode implantation. Furthermore, in the
literature review, we found additional tissue responses such as astrogliosis (53%), multinucleated giant
cells (32%), and neuronal loss (37%). Although these findings are unspecific and were not assessed in our
series, their description, characterization, and role in the therapeutic action of DBS are of great interest.
Support for more postmortem neurohistopathologic after DBS is also supported by our findings of
mistaken diagnosis in our series and the literature. In our study 1 patient was confirmed to have MSA
after DBS implantation for PD, while in the literature, 2 cases[18,30] had an update to MSA after postmortem
assessment. The lack of consistent efficacy in these cases confirms the need for an accurate diagnosis to
obtain the best clinical results. Clinical research would benefit from pathologically confirmed diagnosis to
ensure data is accurate. Additional knowledge about DBS and its mechanisms could allow for the
inclusion of other indications in which the therapy could have potential benefits.

Future directions

Although the neurohistopathological changes observed in the tissue surrounding the DBS electrodes
show characteristics of a classical foreign body reaction, the presence of additional changes (around the
active electrodes) and their underlying mechanisms are yet to be elucidated. The response of different
cellular lines (neurons, glial cells, immune cells, and vasculature-related cells) to electrical stimulation is
not established.[1] Determination of the influence of electrical currents (at varying intensities and charge
densities) on neuronal signaling, neural function, astrocyte response, and overall cellular metabolism
could provide valuable insights to tailor and optimize the stimulation parameters to favor minimal injury,
maximal long-lasting efficacy, and expansion of the contemporary indications for DBS. Additionally, the
development and testing of electrodes (and coatings) with novel functional biomaterials aiming to
minimize the immune response, decrease tissue resistance to stimulation (impedance), favor the attraction
of the neuronal processes (potentially enhancing the benefits of DBS), and optimize the charge transfer
density. Such efforts are underway employing nanomaterials and nanoparticles that minimize the tissue
reaction, favor neural recordings, and improve charge transfer efficiency.[46] Despite this, the use of
postmortem neurohistopathological data continues to provide valuable and fundamental insights to guide
future directions. However, the postmortem literature is largely dominated by studies with low-level
evidence (case reports and case series), lacking standard tissue handling and assessment protocols. The
formation of an integrated network of researchers, the adoption of common protocols for the collection
and management of specimens, and the implementation of new techniques for tissue evaluation seem to
be the natural next step in the evolution of the study of human neurodegenerative and neuropsychiatric
disease and the role of DBS with them.[47,48]

Limitations

We acknowledge that our study has limitations. First, the sample size was small, and the analysis

was retrospective. Next, the clinical outcome data were limited by availability and patient follow-up

Additionally, the handling, processing, and evaluation of the neurohistopathological samples were

performed according to local protocols, which limits the comparison and generalizability of our findings.

Regarding the systematic review, the included studies were small (case reports and series) and

retrospective. The clinical data and postmortem neurohistopathological findings were heterogeneously

reported based on the individual selection and preference of the authors from each study. However,

considering the limited availability of such data and the lack of standardization on the protocols for

neurohistopathological tissue handling, we included all the available reports aiming to comprehensively

summarize the existing literature.

CONCLUSION

Our findings confirm the presence of a local tissue reaction, including gliosis and activated

microglial infiltration around the implanted DBS electrodes. The presence of additional histologic

changes has been reported in the literature however, the implication of these findings needs to be clearly

established. The effect of the local changes on the clinical efficacy of DBS is not clearly established. As

the continual effort to expand the use, efficacy, and safety of DBS for neuromodulation and

neuroaugmentation moves forward, the value of postmortem neurohistopathological evidence will

undoubtedly shed more light on the mechanism behind this powerful clinical and surgical tool. Further

DBS postmortem studies and standardization of tissue processing are needed to expand the understanding

of the interaction between the local brain parenchyma and the implanted DBS electrode.

ACKNOWLEDGMENTS

None

REFERENCES

1.   Evers J, Lowery M. The Active Electrode in the Living Brain: The Response of the Brain Parenchyma to Chronically Implanted Deep Brain Stimulation Electrodes. *Oper Neurosurg (Hagerstown)*. Jan 13 2021;20(2):131-140. doi:10.1093/ons/opaa326

2.   Orlowski D, Michalis A, Glud AN, et al. Brain Tissue Reaction to Deep Brain Stimulation-A Longitudinal Study of DBS in the Goettingen Minipig. *Neuromodulation*. Jul 2017;20(5):417-423. doi:10.1111/ner.12576

3.   Fenoy AJ, Goetz L, Chabardès S, Xia Y. Deep brain stimulation: are astrocytes a key driver behind the scene? *CNS Neurosci Ther*. Mar 2014;20(3):191-201. doi:10.1111/cns.12223

4.   DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case report, and assessment of stimulation threshold safety. *Neuromodulation*. Jul 2014;17(5):405-18; discussion 418. doi:10.1111/ner.12192

5.   Moss J, Ryder T, Aziz TZ, Graeber MB, Bain PG. Electron microscopy of tissue adherent to explanted electrodes in dystonia and Parkinson's disease. *Brain*. Dec 2004;127(Pt 12):2755-63. doi:10.1093/brain/awh292

6.   Al-Helli O, Thomas DL, Massey L, et al. Deep brain stimulation of the subthalamic nucleus: histological verification and 9.4-T MRI correlation. *Acta Neurochir (Wien)*. Dec 2015;157(12):2143-7. doi:10.1007/s00701-015-2599-x

7.   De Vloo P, Thal D, van Kuyck K, Nuttin B. Histopathology after microelectrode recording and twelve years of deep brain stimulation. *Brain Stimul*. Sep-Oct 2018;11(5):1183-1186. doi:10.1016/j.brs.2018.05.005

8.   Vedam-Mai V, Rodgers C, Gureck A, et al. Deep Brain Stimulation associated gliosis: A post-mortem study. *Parkinsonism Relat Disord*. Sep 2018;54:51-55. doi:10.1016/j.parkreldis.2018.04.009

9.   Vedam-Mai V, Martinez-Ramirez D, Hilliard JD, et al. Post-mortem Findings in Huntington's Deep Brain Stimulation: A Moving Target Due to Atrophy. *Tremor Other Hyperkinet Mov (N Y)*. 2016;6:372. doi:10.7916/d8zp462h

10.   Haberler C, Alesch F, Mazal PR, et al. No tissue damage by chronic deep brain stimulation in Parkinson's disease. *Ann Neurol*. Sep 2000;48(3):372-6.

11.   Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disord*. Nov 15 2010;25(15):2649-53. doi:10.1002/mds.23429

12.   Koss AM, Alterman RL, Tagliati M, Shils JL. Calculating total electrical energy delivered by

deep brain stimulation systems. *Ann Neurol*. Jul 2005;58(1):168; author reply 168-9.

doi:10.1002/ana.20525

13.   Fiock KL, Hook J, Hefti MM. Determinants of Astrocytic Pathology in Stem Cell Models of

Primary Tauopathies. *bioRxiv*. Jul 26 2023;doi:10.1101/2023.07.18.549558

14.   Fiock KL, Smalley ME, Crary JF, Pasca AM, Hefti MM. Increased Tau Expression Correlates

with Neuronal Maturation in the Developing Human Cerebral Cortex. *eNeuro*. May/Jun

2020;7(3)doi:10.1523/eneuro.0058-20.2020

15.   Conway KS, Ghafoor F, Gottschalk AC, et al. The Neuropathology of 1p36 Deletion Syndrome:

An Autopsy Case Series. *J Neuropathol Exp Neurol*. Sep 27 2021;80(9):856-860.

doi:10.1093/jnen/nlab072

16.   Wohlin C. Guidelines for snowballing in systematic literature studies and a replication in

software engineering. presented at: Proceedings of the 18th International Conference on Evaluation and

Assessment in Software Engineering; 2014; London, England, United Kingdom.

https://doi.org/10.1145/2601248.2601268

17.   Caparros-Lefebvre D, Ruchoux MM, Blond S, Petit H, Percheron G. Long-term thalamic

stimulation in Parkinson's disease: postmortem anatomoclinical study. *Neurology*. Oct 1994;44(10):1856-

60. doi:10.1212/wnl.44.10.1856

18.   Berciano J, Valldeoriola F, Ferrer I, et al. Presynaptic parkinsonism in multiple system atrophy

mimicking Parkinson's disease: a clinicopathological case study. *Mov Disord*. Jul 2002;17(4):812-6.

doi:10.1002/mds.10190

19.   Jarraya B, Bonnet AM, Duyckaerts C, et al. Parkinson's disease, subthalamic stimulation, and

selection of candidates: a pathological study. *Mov Disord*. Dec 2003;18(12):1517-20.

doi:10.1002/mds.10607

20.   Nielsen MS, Bjarkam CR, Sørensen JC, Bojsen-Møller M, Sunde NA, Østergaard K. Chronic

subthalamic high-frequency deep brain stimulation in Parkinson's disease--a histopathological study. *Eur*

J Neurol. Feb 2007;14(2):132-8. doi:10.1111/j.1468-1331.2006.01569.x

21.   Guehl D, Vital A, Cuny E, et al. POSTMORTEM PROOF OF EFFECTIVENESS OF ZONA

INCERTA STIMULATION IN PARKINSON DISEASE. *Neurology*. 2008;70(16 Part 2):1489-1490.

doi:10.1212/01.wnl.0000310426.18409.11

22.   Gelpi E, Haberler C, Micko A, et al. Focal Subthalamic Atrophy after Long-Term Deep Brain

Stimulation in Parkinson's Disease. *Mov Disord*. Aug 2021;36(8):1987-1989. doi:10.1002/mds.28653

23.   Wright GD, Weller RO. Biopsy and post-mortem findings in a patient receiving cerebellar

stimulation for epilepsy. *J Neurol Neurosurg Psychiatry*. Mar 1983;46(3):266-73.

doi:10.1136/jnnp.46.3.266

24.   Giordano F, Caporalini C, Peraio S, et al. Post-mortem histopathology of a pediatric brain after

bilateral DBS of GPI for status dystonicus: case report and review of the literature. *Childs Nerv Syst*. Sep

2020;36(9):1845-1851. doi:10.1007/s00381-020-04761-w

25.   Gybels J, Dom R, Cosyns P. Electrical stimulation of the central gray for pain relief in human:

autopsy data. *Acta Neurochir Suppl (Wien)*. 1980;30:259-68. doi:10.1007/978-3-7091-8592-6_31

26.   Boivie J, Meyerson BA. A correlative anatomical and clinical study of pain suppression by deep

brain stimulation. *Pain*. Jun 1982;13(2):113-126. doi:10.1016/0304-3959(82)90022-7

27.   Burbaud P, Vital A, Rougier A, et al. Minimal tissue damage after stimulation of the motor

thalamus in a case of chorea-acanthocytosis. *Neurology*. Dec 24 2002;59(12):1982-4.

doi:10.1212/01.wnl.0000038389.30437.1e

28.   Valldeoriola F, Tolosa E, Alegret M, et al. Cognitive changes in Parkinson's disease during

subthalamic stimulation: a clinicopathologic study. *J Neurol Neurosurg Psychiatry*. Apr 2006;77(4):565-

6. doi:10.1136/jnnp.2005.077990

29.   Counelis GJ, Simuni T, Forman MS, Jaggi JL, Trojanowski JQ, Baltuch GH. Bilateral

subthalamic nucleus deep brain stimulation for advanced PD: correlation of intraoperative MER and

postoperative MRI with neuropathological findings. *Mov Disord*. Sep 2003;18(9):1062-5.

doi:10.1002/mds.10489

30.   Chou KL, Forman MS, Trojanowski JQ, Hurtig HI, Baltuch GH. Subthalamic nucleus deep brain

stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. *J Neurosurg*. Mar

2004;100(3):553-6. doi:10.3171/jns.2004.100.3.0553

31.   Sun DA, Yu H, Spooner J, et al. Postmortem analysis following 71 months of deep brain

stimulation of the subthalamic nucleus for Parkinson disease. *J Neurosurg*. Aug 2008;109(2):325-9.

doi:10.3171/jns/2008/109/8/0325

32.   Vedam-Mai V, Yachnis A, Ullman M, Javedan SP, Okun MS. Postmortem observation of

collagenous lead tip region fibrosis as a rare complication of DBS. *Mov Disord*. Apr 2012;27(4):565-9.

doi:10.1002/mds.24916

33.   Pilitsis JG, Chu Y, Kordower J, Bergen DC, Cochran EJ, Bakay RA. Postmortem study of deep

brain stimulation of the anterior thalamus: case report. *Neurosurgery*. Feb 2008;62(2):E530-2; discussion

E532. doi:10.1227/01.neu.0000316024.81786.78

34.   Robertson LT, Dow RS, Cooper IS, Levy LF. Morphological changes associated with chronic
cerebellar stimulation in the human. *J Neurosurg*. Oct 1979;51(4):510-20.
doi:10.3171/jns.1979.51.4.0510

35.   Hosobuchi Y, Adams JE, Linchitz R. Pain relief by electrical stimulation of the central gray
matter in humans and its reversal by naloxone. *Science*. Jul 8 1977;197(4299):183-6.
doi:10.1126/science.301658

36.   Baskin DS, Mehler WR, Hosobuchi Y, Richardson DE, Adams JE, Flitter MA. Autopsy analysis
of the safety, efficacy and cartography of electrical stimulation of the central gray in humans. *Brain Res*.
Apr 23 1986;371(2):231-6. doi:10.1016/0006-8993(86)90358-6

37.   Boockvar JA, Telfeian A, Baltuch GH, et al. Long-term deep brain stimulation in a patient with
essential tremor: clinical response and postmortem correlation with stimulator termination sites in ventral
thalamus. Case report. *J Neurosurg*. Jul 2000;93(1):140-4. doi:10.3171/jns.2000.93.1.0140

38.   Gross RE, Jones EG, Dostrovsky JO, Bergeron C, Lang AE, Lozano AM. Histological analysis of
the location of effective thalamic stimulation for tremor. Case report. *J Neurosurg*. Mar 2004;100(3):547-
52. doi:10.3171/jns.2004.100.3.0547

39.   McClelland S, 3rd, Vonsattel JP, Garcia RE, et al. Relationship of clinical efficacy to
postmortem-determined anatomic subthalamic stimulation in Parkinson syndrome. *Clin Neuropathol*.
Nov-Dec 2007;26(6):267-75. doi:10.5414/npp26267

40.   DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Long-term deep brain stimulation
for essential tremor: 12-year clinicopathologic follow-up. *Mov Disord*. Jan 30 2010;25(2):232-8.
doi:10.1002/mds.22935

41.   Hughes PS, Krcek JP, Hobson DE, Del Bigio MR. An unusual inflammatory response to
implanted deep brain electrodes. *Can J Neurol Sci*. Jan 2011;38(1):168-70.

42.   Henderson JM, O'Sullivan DJ, Pell M, et al. Lesion of thalamic centromedian– parafascicular
complex after chronic deep brain stimulation. *Neurology*. 2001;56(11):1576-1579.
doi:10.1212/wnl.56.11.1576

43.   Henderson JM, Pell M, O'Sullivan DJ, et al. Postmortem analysis of bilateral subthalamic
electrode implants in Parkinson's disease. *Mov Disord*. Jan 2002;17(1):133-7. doi:10.1002/mds.1261

44.   Henderson J, Rodriguez M, O'Sullivan D, et al. Partial lesion of thalamic ventral intermediate
nucleus after chronic high-frequency stimulation. *Mov Disord*. Jun 2004;19(6):709-11.
doi:10.1002/mds.10709

45.   Kuroda R, Nakatani J, Yamada Y, Yorimae A, Kitano M. Location of a DBS-electrode in lateral
thalamus for deafferentation pain. An autopsy case report. *Acta Neurochir Suppl (Wien)*. 1991;52:140-2.
doi:10.1007/978-3-7091-9160-6_38

46.   Angelov SD, Koenen S, Jakobi J, et al. Electrophoretic deposition of ligand-free platinum

nanoparticles on neural electrodes affects their impedance in vitro and in vivo with no negative effect on

reactive gliosis. *J Nanobiotechnology*. Jan 12 2016;14:3. doi:10.1186/s12951-015-0154-9

47.   Vedam-Mai V. Biovalue in Human Brain Banking: Applications and Challenges for Research in

Neurodegenerative Diseases. *Methods Mol Biol*. 2022;2389:209-220. doi:10.1007/978-1-0716-1783-0_17

48.   Vedam-Mai V, Krock N, Ullman M, et al. The national DBS brain tissue network pilot study:

need for more tissue and more standardization. *Cell Tissue Bank*. Aug 2011;12(3):219-31.

doi:10.1007/s10561-010-9189-1

Table 1. Demographic, clinical, and neurohistopathological (around the electrode track) characteristics of the patients who underwent DBS
implantation

DBS case n.	Age at onset/ sex	Disease	Age at DBS	DBS target	Electrode surface material	DBS duration in months [a]	LEDD change [b]	TEED change [c]	Cause of death	Gliosis at DBS site	Activated microglia at DBS lead	Nigra depigmentation	Nigra cell loss	Other neurodegenerative pathology	Other pathology
1	61-65/M	Parkinsonism	66-70	Bilateral subthalamic nucleus	Platinum/ Iridium	24	- 13% (- 200 mg)	+ 2,600% (+ 156 J·s)	Lung cancer	Yes	No	Yes	Yes	None	None
2	46-50/M	Parkinson's disease	66-70	Bilateral subthalamic nucleus	Platinum/ Iridium	140	- 10% (-100 mg)	NA	Unknown	No	No	No	No	• Tau limited to the amygdala • Lewy bodies in the limbic system and cingulate gyrus • Scant TDP-43 inclusions in the hippocampus	None
3	51-55/M	Parkinson's disease	56-60	Bilateral subthalamic nucleus and left ventral intermediate nucleus	Platinum/ Iridium	126 [d]	- 32% (- 350 mg)	+ 233% (+ 221 J·s)	Unknown	Yes	Yes	Yes	No	• Scant Lewy bodies in the cortex and cingulate • Pigment incontinence in the substantia nigra and locus coeruleus	None
4	51-55/M	Parkinson's disease	61-65	Bilateral subthalamic nucleus	Platinum/ Iridium	65	+ 67% (+ 470 mg)	NA	COPD	Yes	No	No	Yes	• Scattered Lewy bodies in the neocortex and amygdala	None
5	46-50/M	Parkinson's disease	51-55	Bilateral subthalamic nucleus	Platinum/ Iridium	262 [e]	- 46% (- 425 mg)	+ 133% (+ 187 J·s)	Unknown	Yes	No	No	Yes	• Lewy bodies in the amygdala and cingulate gyrus • Beta-amyloid plaques in the neocortex (Thal 1) • Neurofibrillary tangles extending into the hippocampus (Braak III/IV) • Scattered subpial astrocytic tau in the neocortex • TDP-43 inclusions in the hippocampus	None
6	56-60/M	Parkinson's disease	61-65	Bilateral globus palidus interna	Platinum/ Iridium	94	+ 213% (+ 1,785 mg)	+ 89% (+ 147 J·s)	Unknown	Yes	No	No	Yes	• Scattered Lewy bodies in the amygdala and cingulate gyrus • Beta-amyloid plaques extending into the basal ganglia (Thal 3, CERAD 1) • Neurofibrillary tangles extending into the primary visual cortex (Braak V/VI)	• Remote hemorrhage in the internal capsule
7	56-60/F	Parkinson's disease	66-70	Bilateral subthalamic nucleus	Platinum/ Iridium	7	NA	NA	Head trauma	No	No	No	Yes	Not assessed	• Intraparenchymal hemorrhages in the basal ganglia, thalamus, corpus callosum, pons, and midbrain
8	56-60/M	Parkinson's disease	61-65	Bilateral subthalamic nucleus	Platinum/ Iridium	13 [f]	- 13% (- 200 mg)	- 2% (- 1 J·s)	Cardiac disease	Yes	No	No	Yes	• Diffuse beta-amyloid plaques in the middle frontal gyrus • Rare neurofibrillary tangles in the hippocampus	• Multifocal subacute infarcts in the middle frontal gyrus and cerebellum with foamy macrophages and gliosis
9	51-55/M	Initial: Parkinson's disease Definitive: MSA – Parkinsonian type	51-55	Bilateral subthalamic nucleus	Platinum/ Iridium	62	- 51% (-1,086 mg)	- 31% (- 21 J·s)	Disease progresion	Yes	No	No	Yes	• Focal Purkinje cell loss and Bergmann gliosis in the cerebellum • Glial cytoplasmic inclusions of alpha synuclein with rare neuronal inclusions in the middle frontal gyrus, cingulate gyrus, corpus callosum, hippocampus, amygdala, pons, substantia nigra, cerebellar white matter, dentate nucleus, and basal ganglia • Rare neurofibrillary tangles in the hippocampus • Scattered tau positive aggregates in the white matter, neocortex, amygdala, substantia nigra, pons, and cerebellum	None

[a] DBS duration was calculated from the first activation until removal or death. [b] LEDD change calculated by subtracting the LEDD at last follow-up minus the one pre-DBS
implantation. [c] TEED change calculated by subtracting the TEDD at last follow-up minus the one at 6 (± 3) months. [d] An additional electrode was implanted due to refractory
right-sided tremor after the initial bilateral subthalamic nucleus stimulation. [e] 198 months after implantation, the patient underwent battery and lead removal due to fluid collections
surrounding the left-sided extracranial DBS wire. Infection was confirmed and managed adequately. Reimplantation to the left side was performed 3 months later. The total time
accounts only for the time when DBS stimulation was active. [f] DBS had to be removed due to chronic wound infection.
Abbreviations: COPD, chronic obstructive pulmonary disease; DBS, deep brain stimulation; F, female; LEDD, Levodopa equivalent daily dose; M, male; MSA, multiple system
atrophy; n., number; NA, not available, TEED, total electrical energy delivered.

Table 2. Characteristics of the postmortem neurohistopathological findings around the DBS electrode track for Parkinson's disease

Author, year	DBS case n.	Age at DBS	Sex	DBS targets	Electrode surface material	Clinical efficacy after DBS	Clinical decline after DBS	DBS duration in months	Cause of death	Gliosis at DBS site	Activated microglia at DBS lead	Neuronal loss at DBS site	Other findings at DBS site	Nigra depigmentaion	Nigra cell loss
Caparros-Lefebvre et al., 1994[17]	1	56-60	M	Vim	Pt/Ir	Yes	No	43	Stroke	Yes (1 mm perimeter)	NR	NR	Accumulation of lymphoid cells, macrophages, and giant cells (2 mm) around the electrode	Yes	Yes
Haberler et al., 2000[10]	2	NR	NR	L Vim	Pt/Ir	Yes	No	70	Myocardial infarction	Yes	No	No	-	Yes	Yes
"	3	71-75	M	BL Vim	Pt/Ir	Yes	No	54	Cardiovascular failure	Yes	No	No	Mononuclear leukocytes	Yes	Yes
"	4	51-55	M	L Vim	Pt/Ir	Yes	No	45	Cardiovascular failure	Yes	No	No	Macrophages and reactive astrocytes	Yes	Yes
"	5	56-60	M	BL Vim	Pt/Ir	Yes	No	45	Cardiovascular failure	Yes	NR	No	Multinucleated giant cells and reactive astrocytes	Yes	Yes
"	6	41-45	M	R Vim	Pt/Ir	Yes	No	1	Astrocytoma	Yes	NR	No	Multinucleated giant cells	Yes	Yes
"	7	76-80	M	BL Vim	Pt/Ir	Yes	No	15	Cardiovascular failure	Yes	Yes	No	More pronounced gliosis around lead track, multinucleated giant cells, and reactive astrocytes	Yes	Yes
"	8	66-70	F	BL STN	Pt/Ir	Yes	No	3	Drowning	Yes	Yes	No	More pronounced gliosis around lead track, multinucleated giant cells, and reactive astrocytes	Yes	Yes
"	9	61-65	M	L STN	Pt/Ir	Yes	No	2 days	Myocardial infarction	-	No	No	Fresh hemorrhage, perifocal edema, and numerous axonal spheroids	Yes	Yes
Henderson et al., 2001[42]	10	66-70	M	L CM-Pf	Pt/Ir	Yes	Yes	48	Sepsis	Yes	NR	Yes	Extensive astrocytosis and small thalamotomy greater than the dimension of the electrode tip penetration	Yes	Yes
Berciano et al., 2002[18]	11*	61-65	M	BL STN	NR	Yes	No	21 days	Pulmonary embolus	NR	NR	NR	NR	Yes	Yes
Henderson et al., 2002[43]	12	51-55	M	BL STN	Pt/Ir	Yes	No	2	Aspiration pneumonia	Yes	Yes	Yes (mild)	TUNEL staining and analysis of cellular morphology did not show features of apoptosis, and astrocytosis	Yes	Yes
Counelis et al., 2003[29]	13	61-65	M	BL STN	Pt/Ir	Yes	-	4 days	Pulmonary embolus	No	No	No	Fresh hemorrhage along tracks and minimal reactive changes	NR	Yes
Jarraya et al., 2003[19]	14	21-25	F	BL STN	NR	Yes	Yes	24	Pulmonary embolus	Yes	NR	NR	Large number of activated macrophages around the cavity and in the vicinity, and astrocytosis	Yes	Yes
Chou et al., 2004[30]	15*	51-55	M	BL STN	NR	No	Yes	3	Aspiration pneumonia	Yes	NR	NR	Tracks associated with hemosiderin deposition, multinucleated giant cells, and neovascularization	Yes	Yes
Henderson et al., 2004[44]	16	61-65	M	L Vim	Pt/Ir	Yes	Yes	84	Ischemic heart disease	Yes	No	Yes	Hemosiderin deposition along the electrode track and astrocytosis	Yes	Yes
Nielsen et al., 2007[20]	17	71-75	M	BL STN	Pt/Ir	Yes	No	29	Accident	Yes (capsule)	NR	No	Lymphocytes, macrophages, neutrophilic granulocytes, occasional neurons in the capsule, and astrocytosis	Yes	Yes
Guehl et al., 2008[21]	18	51-55	M	BL ZI	Pt/Ir	Yes	No	72	Dystonia (rhabdomyolysis)	Yes	NR	NR	None of the electrode contacts were located within the STN	NR	NR

Study	n.	Age	Sex	Target	Material					Cause of death				Histopathology		
Sun et al., 2008[31]	19	81-85	M	BL STN	Pt/Ir	Yes	No		71	Pnemonia	Yes	Yes	NR	Capsule with hemosiderin-laden macrophages, scattered lymphocytes, Rosenthal fibers, focal foreign-body giant cell reaction, and astrocytosis	Yes	Yes
Vedam-Mai et al., 2012[32]	20	71-75	M	BL STN	NR	Yes	No		13	Cardiac arrest	Yes	No	No	Marked fibrosis around the cavity (right DBS lead tip), fibrocollagenous "capsule" confirmed by Mason's trichrome	Yes	Yes
Al-Helli et al., 2015[6]	21	66-70	M	BL STN	NR	NR	NR		72	NR	Yes	Yes	NR	Small collagenous scar with gliosis (Perl's stain positive) around track	Yes	Yes[6]
De Vloo et al., 2018[7]	22	66-70	F	BL STN	Pt/Ir	Yes	No		144	Pneumonia	Yes	No	No	Minimal reactive astrocytosis, macrophages, fibrillary gliosis, and perivascular lymphocytic infiltration	Yes	Yes
Gelpi et al., 2021[22]	23	61-65	M	BL STN	NR	Yes	No		51	Peritonitis	Yes	Yes	Yes	Astrogliosis	Yes	NR
"	24	66-70	F	BL STN	NR	Yes	No		52	Pneumonia	Yes	Yes	Yes	Rosenthal fibers and astrogliosis	Yes	NR
"	25	46-50	M	BL STN	NR	Yes	No		36	Pneumonia	Yes	Yes	Yes	Multinucleated giant cells, Rosenthal fibers, and astrogliosis	Yes	NR
"	26	51-55	M	BL STN	NR	Yes	No		48	Cardiac arrest	Yes	Yes	Yes	Rosenthal fibers and astrogliosis	Yes	NR

489 * DBS indicated for PD, but postmortem examination established diagnosis of multiple system atrophy

490 Abbreviations: BL, bilateral; CM-Pf, centromedian-parafasicular complex thalamic region; DBS, deep brain stimulation; F, female; L, left; M, male; n., number;

491 NR, not reported; Pt/Ir, platinum/iridium; R, right; STN, subthalamic nucleus; TUNEL, (TdT)-mediated UTP nick and labelling; Vim, ventralis intermedius

492 thalamic nucleus; ZI, zona incerta.

FIGURES AND FIGURE LEGENDS

[Figure 1 (A-E).](#) **Macroscopic and microscopic tissue representations.** (**A**) Coronal brain slice depicting gross bilateral tracts with close-up pop-out. Arrows denote tracts. (**B**) Hematoxylin & Eosin stain slide of midbrain with electrode tract in the nigra. Black scale=200um. (**C**) Lewy bodies in the nigra, arrow denotes Lewy body. White scale=50um. (**D**) Luxol fast blue stain on thalamus with electrode tract. Black scale=200um. (**E**) Glial fibrillary acidic protein statin on thalamus with tract. Black scale=200um.